{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:16:23Z","timestamp":1784211383094,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"am","delay-in-days":334,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R35-GM132072"],"award-info":[{"award-number":["R35-GM132072"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jconrel.2023.05.026","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T12:40:42Z","timestamp":1685450442000},"page":"26-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Lipidation of a bioactive cyclotide-based CXCR4 antagonist greatly improves its pharmacokinetic profile in vivo"],"prefix":"10.1016","volume":"359","author":[{"given":"Dipankar","family":"Chaudhuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiangong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binu","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sojan","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Premlata","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Poss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouri","family":"Neamati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio A.","family":"Camarero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.05.026_bb0005","doi-asserted-by":"crossref","first-page":"7975","DOI":"10.1158\/1078-0432.CCR-07-4846","article-title":"Translating an antagonist of chemokine receptor CXCR4: from bench to bedside","volume":"14","author":"Wong","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0010","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/84298","article-title":"Chemokines: immunology\u2019s high impact factors","volume":"2","author":"Mackay","year":"2001","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0015","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/ni.f.214","article-title":"Chemokines and leukocyte traffic","volume":"9","author":"Sallusto","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.it.2003.12.005","article-title":"Chemokines: multiple levels of leukocyte migration control","volume":"25","author":"Moser","year":"2004","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0025","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1158\/1078-0432.CCR-09-2329","article-title":"CXCL12 (SDF-1)\/CXCR4 pathway in cancer","volume":"16","author":"Teicher","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/B978-0-12-411638-2.00002-1","article-title":"The intricate role of CXCR4 in cancer","volume":"124","author":"Chatterjee","year":"2014","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0035","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.breast.2004.12.007","article-title":"The elevated level of CXCR4 is correlated with nodal metastasis of human breast cancer","volume":"14","author":"Kang","year":"2005","journal-title":"Breast"},{"key":"10.1016\/j.jconrel.2023.05.026_bb0040","doi-asserted-by":"crossref","first-page":"R144","DOI":"10.1186\/bcr627","article-title":"Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma","volume":"5","author":"Kato","year":"2003","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0045","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1126\/science.272.5263.872","article-title":"HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor","volume":"272","author":"Feng","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2023.05.026_bb0050","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/382833a0","article-title":"The CXC chemokine SDF-1 is the ligand for LESTR\/fusin and prevents infection by T-cell-line-adapted HIV-1","volume":"382","author":"Oberlin","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2023.05.026_bb0055","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/cbin.10631","article-title":"CXCR4 and CCR7: two eligible targets in targeted cancer therapy","volume":"40","author":"Mishan","year":"2016","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0060","first-page":"4953","article-title":"CXCR4 in breast cancer: oncogenic role and therapeutic targeting","volume":"9","author":"Xu","year":"2015","journal-title":"Drug. Des. Devel. Ther."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0065","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1021\/jm200568c","article-title":"Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4)","volume":"55","author":"Choi","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0070","doi-asserted-by":"crossref","first-page":"22255","DOI":"10.1073\/pnas.1009633108","article-title":"Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells","volume":"107","author":"Tchernychev","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0075","doi-asserted-by":"crossref","first-page":"15878","DOI":"10.1021\/ja206661w","article-title":"Direct interaction between an allosteric agonist pepducin and the chemokine receptor CXCR4","volume":"133","author":"Janz","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0080","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1189\/jlb.2MR1115-521RR","article-title":"Proteolytic processing of human serum albumin generates EPI-X4, an endogenous antagonist of CXCR4","volume":"99","author":"Zirafi","year":"2016","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232315029","article-title":"Advanced EPI-X4 derivatives covalently bind human serum albumin resulting in prolonged plasma stability","volume":"23","author":"Rodriguez-Alfonso","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0090","doi-asserted-by":"crossref","first-page":"10729","DOI":"10.1021\/jm301468k","article-title":"Design of a novel cyclotide-based CXCR4 antagonist with anti-human immunodeficiency virus (HIV)-1 activity","volume":"55","author":"Aboye","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0095","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/leu.2008.299","article-title":"CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers","volume":"23","author":"Burger","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.jconrel.2023.05.026_bb0100","doi-asserted-by":"crossref","first-page":"FDD77","DOI":"10.4155\/fdd-2022-0007","article-title":"CXCR4 as a novel target in immunology: moving away from typical antagonists","volume":"4","author":"Caspar","year":"2022","journal-title":"Future Drug Discov."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0105","doi-asserted-by":"crossref","first-page":"14469","DOI":"10.1002\/chem.201702540","article-title":"In vivo evaluation of an engineered cyclotide as specific CXCR4 imaging reagent","volume":"23","author":"Lesniak","year":"2017","journal-title":"Chemistry"},{"key":"10.1016\/j.jconrel.2023.05.026_bb0110","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.addr.2009.05.003","article-title":"Discovery, structure and biological activities of cyclotides","volume":"61","author":"Daly","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0115","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.2174\/138161211798999438","article-title":"Cyclotides, a novel ultrastable polypeptide scaffold for drug discovery","volume":"17","author":"Gould","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.phytochem.2021.113053","article-title":"Comparative analysis of cyclotide-producing plant cell suspensions presents opportunities for cyclotide plant molecular farming","volume":"195","author":"Doffek","year":"2022","journal-title":"Phytochemistry"},{"key":"10.1016\/j.jconrel.2023.05.026_bb0125","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/978-1-0716-0434-2_16","article-title":"Recombinant expression of cyclotides using expressed protein ligation","volume":"2133","author":"Campbell","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0130","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-1-4939-6451-2_4","article-title":"Recombinant expression of cyclotides using split inteins","volume":"1495","author":"Jagadish","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0135","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/bs.abr.2015.08.006","article-title":"Chemical and biological production of cyclotides","volume":"76","author":"Li","year":"2015","journal-title":"Adv. Bot. Res."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0140","doi-asserted-by":"crossref","first-page":"18481","DOI":"10.1021\/jacs.1c07574","article-title":"An ultrapotent and selective cyclic peptide inhibitor of human beta-factor XIIa in a cyclotide scaffold","volume":"143","author":"Liu","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076956","article-title":"Combinatorial optimization of cystine-knot peptides towards high-affinity inhibitors of human matriptase-1","volume":"8","author":"Glotzbach","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2023.05.026_bb0150","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1021\/cb4000585","article-title":"Design of a cyclotide antagonist of neuropilin-1 and -2 that potently inhibits endothelial cell migration","volume":"8","author":"Getz","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0155","doi-asserted-by":"crossref","first-page":"11623","DOI":"10.1021\/ja405108p","article-title":"In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide","volume":"135","author":"Ji","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines7020031","article-title":"The potential of the cyclotide scaffold for drug development","volume":"7","author":"Camarero","year":"2019","journal-title":"Biomedicines"},{"key":"10.1016\/j.jconrel.2023.05.026_bb0165","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1042\/BCJ20180792","article-title":"Using backbone-cyclized Cys-rich polypeptides as molecular scaffolds to target protein-protein interactions","volume":"476","author":"Chaudhuri","year":"2019","journal-title":"Biochem. J."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0170","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ijpharm.2019.05.001","article-title":"Pharmacokinetic characterization of kalata B1 and related therapeutics built on the cyclotide scaffold","volume":"565","author":"Poth","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2018.12.032","article-title":"A review of lipidation in the development of advanced protein and peptide therapeutics","volume":"295","author":"Menacho-Melgar","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.05.026_bb0180","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0185","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/cbic.201402691","article-title":"Rapid parallel synthesis of bioactive folded cyclotides by using a tea-bag approach","volume":"16","author":"Aboye","year":"2015","journal-title":"Chembiochem"},{"key":"10.1016\/j.jconrel.2023.05.026_bb0190","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1073\/pnas.94.5.1925","article-title":"The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes","volume":"94","author":"Bleul","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0195","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.18632\/oncotarget.6465","article-title":"Ulocuplumab (BMS-936564 \/ MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway","volume":"7","author":"Kashyap","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2023.05.026_bb0200","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1038\/srep06610","article-title":"A designed peptide targeting CXCR4 displays anti-acute myelocytic leukemia activity in vitro and in vivo","volume":"4","author":"Li","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2023.05.026_bb0205","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1021\/jm9909645","article-title":"Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration","volume":"43","author":"Knudsen","year":"2000","journal-title":"J. Med. Chem."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923003395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923003395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:42:39Z","timestamp":1759164159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923003395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":41,"alternative-id":["S0168365923003395"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.05.026","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipidation of a bioactive cyclotide-based CXCR4 antagonist greatly improves its pharmacokinetic profile in vivo","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.05.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}